Personalized genomic analyses for cancer mutation discovery and interpretation.
Personalized genomic analyses for cancer mutation discovery and interpretation.
复制标题
DOI:
10.1126/scitranslmed.aaa7161
复制
发表时间:
2015-04-15
影响因子:
17.1
通讯作者:
Velculescu VE
中科院分区:
文献类型:
--
作者:
Jones S;Anagnostou V;Lytle K;Parpart-Li S;Nesselbush M;Riley DR;Shukla M;Chesnick B;Kadan M;Papp E;Galens KG;Murphy D;Zhang T;Kann L;Sausen M;Angiuoli SV;Diaz LA Jr;Velculescu VE
Massively parallel sequencing approaches are beginning to be used clinically to characterize individual patient tumors and to select therapies based on the identified mutations. A major question in these analyses is the extent to which these methods identify clinically actionable alterations and whether the examination of the tumor tissue alone is sufficient or whether matched normal DNA should also be analyzed to accurately identify tumor-specific (somatic) alterations. To address these issues, we comprehensively evaluated 815 tumor-normal paired samples from patients of 15 tumor types. We identified genomic alterations using next-generation sequencing of whole exomes or 111 targeted genes that were validated with sensitivities >95% and >99%, respectively, and specificities >99.99%. These analyses revealed an average of 140 and 4.3 somatic mutations per exome and targeted analysis, respectively. More than 75% of cases had somatic alterations in genes associated with known therapies or current clinical trials. Analyses of matched normal DNA identified germline alterations in cancer-predisposing genes in 3% of patients with apparently sporadic cancers. In contrast, a tumor-only sequencing approach could not definitively identify germline changes in cancer-predisposing genes and led to additional false-positive findings comprising 31% and 65% of alterations identified in targeted and exome analyses, respectively, including in potentially actionable genes. These data suggest that matched tumor-normal sequencing analyses are essential for precise identification and interpretation of somatic and germline alterations and have important implications for the diagnostic and therapeutic management of cancer patients.
登录
查看更多内容
影响因子:
11.2
作者:
Carter H;Chen S;Isik L;Tyekucheva S;Velculescu VE;Kinzler KW;Vogelstein B;Karchin R
通讯作者:
Karchin R
DOI:
10.1126/science.1200609
发表时间:
2011-03-04
期刊:
Science (New York, N.Y.)
影响因子:
--
作者:
Jiao Y;Shi C;Edil BH;de Wilde RF;Klimstra DS;Maitra A;Schulick RD;Tang LH;Wolfgang CL;Choti MA;Velculescu VE;Diaz LA Jr;Vogelstein B;Kinzler KW;Hruban RH;Papadopoulos N
通讯作者:
Papadopoulos N
DOI:
10.1073/pnas.0712345105
发表时间:
2008-03-18
影响因子:
11.1
作者:
Jones, Sian;Chen, Wei-dong;Markowitz, Sanford D.
通讯作者:
Markowitz, Sanford D.
影响因子:
46.9
作者:
Frampton GM;Fichtenholtz A;Otto GA;Wang K;Downing SR;He J;Schnall-Levin M;White J;Sanford EM;An P;Sun J;Juhn F;Brennan K;Iwanik K;Maillet A;Buell J;White E;Zhao M;Balasubramanian S;Terzic S;Richards T;Banning V;Garcia L;Mahoney K;Zwirko Z;Donahue A;Beltran H;Mosquera JM;Rubin MA;Dogan S;Hedvat CV;Berger MF;Pusztai L;Lechner M;Boshoff C;Jarosz M;Vietz C;Parker A;Miller VA;Ross JS;Curran J;Cronin MT;Stephens PJ;Lipson D;Yelensky R
通讯作者:
Yelensky R
影响因子:
30.8
作者:
Jiao, Yuchen;Pawlik, Timothy M.;Anders, Robert A.;Selaru, Florin M.;Streppel, Mirte M.;Lucas, Donald J.;Niknafs, Noushin;Guthrie, Violeta Beleva;Maitra, Anirban;Argani, Pedram;Offerhaus, G. Johan A.;Roa, Juan Carlos;Roberts, Lewis R.;Gores, Gregory J.;Popescu, Irinel;Alexandrescu, Sorin T.;Dima, Simona;Fassan, Matteo;Simbolo, Michele;Mafficini, Andrea;Capelli, Paola;Lawlor, Rita T.;Ruzzenente, Andrea;Guglielmi, Alfredo;Tortora, Giampaolo;de Braud, Filippo;Scarpa, Aldo;Jarnagin, William;Klimstra, David;Karchin, Rachel;Velculescu, Victor E.;Hruban, Ralph H.;Vogelstein, Bert;Kinzler, Kenneth W.;Papadopoulos, Nickolas;Wood, Laura D.
通讯作者:
Wood, Laura D.